Areas identified as non-malignant (e.g. Figure 1 panel 1, upper left and panel 2, bottom right) or benign prostatic hyperplasia (BPH) showed no or faint TRPM4 immunoreactivity. This evidence concerns the gene TRPM4 and benign prostatic hyperplasia.